News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Hydra Biosciences, Inc. And Boehringer Ingelheim Corporation Announce Worldwide Collaboration To Develop Small-Molecule Inhibitors For The Treatment Of Central Nervous System Diseases And Disorders


4/24/2014 9:54:14 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass. & INGELHEIM, Germany--(BUSINESS WIRE)--Hydra Biosciences, Inc., a leader in the field of Transient Receptor Potential (TRP) channel modulation, and Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, jointly announced today that they have entered into a worldwide collaboration to research and develop small-molecule TRPC4/5 inhibitors for the treatment of central nervous system (CNS) diseases and disorders.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES